Your browser doesn't support javascript.
loading
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study.
Thiem, Alexander; Mashhadiakbar, Pegah; Cussigh, Christiane; Hassel, Jessica C; Grimmelmann, Imke; Gutzmer, Ralf; Schlaak, Max; Heppt, Markus V; Dücker, Pia; Hüning, Svea; Schulmeyer, Lena; Schilling, Bastian; Haferkamp, Sebastian; Ziemer, Mirjana; Moritz, Rose K C; Hagelstein, Victoria; Terheyden, Patrick; Posch, Christian; Gaiser, Maria R; Kropp, Peter; Emmert, Steffen; Müller, Britta; Tietze, Julia K.
Afiliação
  • Thiem A; Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.
  • Mashhadiakbar P; Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.
  • Cussigh C; Department of Dermatology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Hassel JC; Department of Dermatology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Grimmelmann I; Department of Dermatology, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
  • Gutzmer R; Department of Dermatology, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
  • Schlaak M; Department of Dermatology, Skin Cancer Center Minden, Johannes-Wesling-Klinikum Minden/Ruhr-University, Bochum, Minden, Germany.
  • Heppt MV; Department of Dermatology and Allergy, University Hospital of Munich (LMU), Munich, Germany.
  • Dücker P; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Hüning S; Department of Dermatology, Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
  • Schulmeyer L; Department of Dermatology, Hospital of Dortmund, Dortmund, Germany.
  • Schilling B; Department of Dermatology, Hospital of Dortmund, Dortmund, Germany.
  • Haferkamp S; Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
  • Ziemer M; Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
  • Moritz RKC; Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
  • Hagelstein V; Department of Dermatology, Venereology and Allergology, University Medical Center Leipzig, Leipzig, Germany.
  • Terheyden P; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Posch C; Department of Dermatology and Venereology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
  • Gaiser MR; Department of Dermatology, Allergology, and Venereology, University of Lübeck, Lübeck, Germany.
  • Kropp P; Department of Dermatology, Allergology, and Venereology, University of Lübeck, Lübeck, Germany.
  • Emmert S; Department of Dermatology, Venereology and Allergology, Clinic Hietzing, Vienna Healthcare Group, Vienna, Austria.
  • Müller B; Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK), Technical University of Munich, Munich, Germany.
  • Tietze JK; Faculty of Medicine, Sigmund Freud University Vienna, Vienna, Austria.
J Eur Acad Dermatol Venereol ; 37(5): 884-893, 2023 May.
Article em En | MEDLINE | ID: mdl-36433671
BACKGROUND: Choosing the adequate systemic treatment for melanoma is driven by clinical parameters and personal preferences. OBJECTIVE: Evaluation of the impact of disease and treatment on the daily life of patients receiving systemic therapy for melanoma. METHODS: A German-wide, cross-sectional comparative study was conducted at 13 specialized skin cancer centres from 08/2020 to 03/2021. A questionnaire was distributed to assess patients' perception of disease and symptoms, the impact of their current treatment on quality of life (QOL) and activities, adverse events (AEs), therapeutic visits, as well as believe in and satisfaction with their current systemic melanoma treatment. Patient-reported outcomes (PROs) were rated on a continuous numerical rating scale or selected from a given list. RESULTS: Four hundred and fourteen patients with systemic melanoma therapy were included. 359 (87%) received immune checkpoint inhibition (ICI) and 55 (13%) targeted therapy (TT). About 1/3 of patients were adjuvantly treated, the remaining because of unresectable/metastatic melanoma. In subgroup analyses, only in the adjuvant setting, TT patients reported a significant decrease in their treatment associated QOL compared to patients with ICI (p = 0.02). Patients with TT were 1.9 times more likely to report AEs than patients with ICI, a difference being significant just for the adjuvant setting (p = 0.01). ICI treatment intervals differed significantly between adjuvant and unresectable/metastatic setting (p = 0.04), though all patients, regardless of their specific ICI drug, evaluated their treatment frequency as adequate. TT patients with dabrafenib/trametinib (n = 37) or encorafenib/binimetinib (n = 15) did not differ regarding the strain of daily pill intake. Patients older than 63 years rated various PROs better than younger patients. CONCLUSIONS: Patients evaluated their treatment mainly positively. ICI might be preferred over TT regarding QOL and patient-reported AEs in the adjuvant setting. Older melanoma patients appeared to be less impacted by their disease and more satisfied with their treatment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Prevalence_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Prevalence_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article